Pharmacodynamics<unk>  acts as an agonist of dopamine D2 and D1 and serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C receptors. It may possess agonist activity at other dopamine receptor subtypes as well, similar to cabergoline. Although<unk>  is more potent as an agonist of the D2 receptor, it has high D1 receptor affinity and is one of the most potent D1 receptor agonists of the dopamine receptor agonists that are clinically available. The agonist activity of<unk>  at the D1 receptor somewhat alters its clinical and side effect profile in the treatment of Parkinson's disease.<unk>  is said to be hallucinogenic due to activation of 5-HT2A receptors. It has been associated with cardiac valvulopathy due to activation of 5-HT2B receptors. + Site Affinity (Ki nM) Efficacy (Emax %) Action D1 339 ? ? D2S 32 112 Full agonist D2L 26 52 Partial agonist D3 5.5 71 Partial agonist D4 59 56 Partial agonist D5 33 ? ? 5-HT1A 1.9 63 Partial agonist 5-HT1B 282 90 Partial agonist 5-HT1D 13 86 Partial agonist 5-HT2A 8.3 103 Full agonist 5-HT2B 7.1 113 Full agonist 5-HT2C 295 87 Partial agonist 5-HT6 30 ? ? 5-HT7 1.0–18 ? ? α1A 1,047 ? ? α1B 692 ? ? α1D 295 ? ? α2A 50 31 Partial agonist α2B 32 70 Partial agonist α2C 68 16 Partial agonist α2D 692 ? ? β1 >10,000 – – β2 >10,000 – – H1 1,698 ? ? M1 >10,000 – – σ1 >10,000 – – σ2 923 ? ? Notes: All receptors are human except α2D-adrenergic, which is rat (no human counterpart), and 5-HT6, 5-HT7, σ1, and σ2, which are all rodent (rat or guinea pig).
Pergolide
Quinagolide
Enarodustat
Endrisone
Golodirsen
Eliglustat
Miglustat
Roxadustat